ID   STK11_HUMAN             Reviewed;         433 AA.
AC   Q15831; B2RBX7; E7EW76;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   21-MAR-2012, entry version 135.
DE   RecName: Full=Serine/threonine-protein kinase STK11;
DE            EC=2.7.11.1;
DE   AltName: Full=Liver kinase B1;
DE            Short=LKB1;
DE            Short=hLKB1;
DE   AltName: Full=Renal carcinoma antigen NY-REN-19;
GN   Name=STK11; Synonyms=LKB1, PJS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND INVOLVEMENT IN PJS.
RC   TISSUE=Liver;
RX   MEDLINE=98085866; PubMed=9425897; DOI=10.1038/ng0198-38;
RA   Jenne D.E., Reimann H., Nezu J., Friedl W., Loff S., Jeschke R.,
RA   Mueller O., Back W., Zimmer M.;
RT   "Peutz-Jeghers syndrome is caused by mutations in a novel serine
RT   threonine kinase.";
RL   Nat. Genet. 18:38-43(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=98196525; PubMed=9537235;
RA   Bignell G.R., Barfoot R., Seal S., Collins N., Warren W.,
RA   Stratton M.R.;
RT   "Low frequency of somatic mutations in the LKB1/Peutz-Jeghers syndrome
RT   gene in sporadic breast cancer.";
RL   Cancer Res. 58:1384-1386(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   IDENTIFICATION AS A RENAL CANCER ANTIGEN.
RC   TISSUE=Renal cell carcinoma;
RX   MEDLINE=99438124; PubMed=10508479;
RX   DOI=10.1002/(SICI)1097-0215(19991112)83:4<456::AID-IJC4>3.0.CO;2-5;
RA   Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H.,
RA   Jongeneel C.V., Gure A.O., Jaeger D., Jaeger E., Knuth A., Chen Y.-T.,
RA   Old L.J.;
RT   "Antigens recognized by autologous antibody in patients with renal-
RT   cell carcinoma.";
RL   Int. J. Cancer 83:456-464(1999).
RN   [8]
RP   INVOLVEMENT IN LUNG CANCER.
RX   PubMed=11212897; DOI=10.1023/A:1006442024874;
RA   Sobottka S.B., Haase M., Fitze G., Hahn M., Schackert H.K.,
RA   Schackert G.;
RT   "Frequent loss of heterozygosity at the 19p13.3 locus without
RT   LKB1/STK11 mutations in human carcinoma metastases to the brain.";
RL   J. Neurooncol. 49:187-195(2000).
RN   [9]
RP   IDENTIFICATION IN A TERNARY COMPLEX COMPOSED OF SMAD4 AND STK11IP, AND
RP   INTERACTION WITH SMAD4 AND STK11IP.
RX   MEDLINE=21617222; PubMed=11741830; DOI=10.1093/hmg/10.25.2869;
RA   Smith D.P., Rayter S.I., Niederlander C., Spicer J., Jones C.M.,
RA   Ashworth A.;
RT   "LIP1, a cytoplasmic protein functionally linked to the Peutz-Jeghers
RT   syndrome kinase LKB1.";
RL   Hum. Mol. Genet. 10:2869-2877(2001).
RN   [10]
RP   SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, FUNCTION, MUTAGENESIS OF
RP   LYS-78 AND THR-189, AND PHOSPHORYLATION AT THR-189.
RX   PubMed=11430832; DOI=10.1016/S1097-2765(01)00258-1;
RA   Karuman P., Gozani O., Odze R.D., Zhou X.C., Zhu H., Shaw R.,
RA   Brien T.P., Bozzuto C.D., Ooi D., Cantley L.C., Yuan J.;
RT   "The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent
RT   cell death.";
RL   Mol. Cell 7:1307-1319(2001).
RN   [11]
RP   INVOLVEMENT IN LUNG CANCER.
RX   PubMed=12097271;
RA   Sanchez-Cespedes M., Parrella P., Esteller M., Nomoto S., Trink B.,
RA   Engles J.M., Westra W.H., Herman J.G., Sidransky D.;
RT   "Inactivation of LKB1/STK11 is a common event in adenocarcinomas of
RT   the lung.";
RL   Cancer Res. 62:3659-3662(2002).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH STRADA,
RP   AUTOPHOSPHORYLATION AT THR-336 AND THR-363, AND CHARACTERIZATION OF
RP   VARIANT SPORADIC CANCER TYR-176.
RX   MEDLINE=22688956; PubMed=12805220; DOI=10.1093/emboj/cdg292;
RA   Baas A.F., Boudeau J., Sapkota G.P., Smit L., Medema R., Morrice N.A.,
RA   Alessi D.R., Clevers H.C.;
RT   "Activation of the tumour suppressor kinase LKB1 by the STE20-like
RT   pseudokinase STRAD.";
RL   EMBO J. 22:3062-3072(2003).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, MUTAGENESIS OF ASP-194, IDENTIFICATION
RP   IN A COMPLEX WITH STRADA AND CAB39, AND INTERACTION WITH STRADA;
RP   STRADB; CAB39 AND CAB39L.
RX   PubMed=14517248; DOI=10.1093/emboj/cdg490;
RA   Boudeau J., Baas A.F., Deak M., Morrice N.A., Kieloch A.,
RA   Schutkowski M., Prescott A.R., Clevers H.C., Alessi D.R.;
RT   "MO25alpha/beta interact with STRADalpha/beta enhancing their ability
RT   to bind, activate and localize LKB1 in the cytoplasm.";
RL   EMBO J. 22:5102-5114(2003).
RN   [14]
RP   FUNCTION IN CELL POLARITY.
RX   PubMed=15016379; DOI=10.1016/S0092-8674(04)00114-X;
RA   Baas A.F., Kuipers J., van der Wel N.N., Batlle E., Koerten H.K.,
RA   Peters P.J., Clevers H.C.;
RT   "Complete polarization of single intestinal epithelial cells upon
RT   activation of LKB1 by STRAD.";
RL   Cell 116:457-466(2004).
RN   [15]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF ASP-194.
RX   PubMed=14976552; DOI=10.1038/sj.emboj.7600110;
RA   Lizcano J.M., Goeransson O., Toth R., Deak M., Morrice N.A.,
RA   Boudeau J., Hawley S.A., Udd L., Maekelae T.P., Hardie D.G.,
RA   Alessi D.R.;
RT   "LKB1 is a master kinase that activates 13 kinases of the AMPK
RT   subfamily, including MARK/PAR-1.";
RL   EMBO J. 23:833-843(2004).
RN   [16]
RP   INVOLVEMENT IN LUNG CANCER.
RX   PubMed=15021901; DOI=10.1038/sj.onc.1207502;
RA   Carretero J., Medina P.P., Pio R., Montuenga L.M.,
RA   Sanchez-Cespedes M.;
RT   "Novel and natural knockout lung cancer cell lines for the LKB1/STK11
RT   tumor suppressor gene.";
RL   Oncogene 23:4037-4040(2004).
RN   [17]
RP   FUNCTION.
RX   PubMed=15733851; DOI=10.1016/j.febslet.2005.01.042;
RA   Jaleel M., McBride A., Lizcano J.M., Deak M., Toth R., Morrice N.A.,
RA   Alessi D.R.;
RT   "Identification of the sucrose non-fermenting related kinase SNRK, as
RT   a novel LKB1 substrate.";
RL   FEBS Lett. 579:1417-1423(2005).
RN   [18]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH TP53.
RX   PubMed=17108107; DOI=10.1158/0008-5472.CAN-06-0999;
RA   Zeng P.Y., Berger S.L.;
RT   "LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate
RT   transcriptional activation.";
RL   Cancer Res. 66:10701-10708(2006).
RN   [19]
RP   INTERACTION WITH WDR6.
RX   PubMed=17216128; DOI=10.1007/s11010-006-9402-5;
RA   Xie X., Wang Z., Chen Y.;
RT   "Association of LKB1 with a WD-repeat protein WDR6 is implicated in
RT   cell growth arrest and p27(Kip1) induction.";
RL   Mol. Cell. Biochem. 301:115-122(2007).
RN   [20]
RP   INVOLVEMENT IN LUNG CANCER.
RX   PubMed=17711506; DOI=10.1111/j.1349-7006.2007.00585.x;
RA   Onozato R., Kosaka T., Achiwa H., Kuwano H., Takahashi T., Yatabe Y.,
RA   Mitsudomi T.;
RT   "LKB1 gene mutations in Japanese lung cancer patients.";
RL   Cancer Sci. 98:1747-1751(2007).
RN   [21]
RP   INVOLVEMENT IN LUNG CANCER.
RX   PubMed=17676035; DOI=10.1038/nature06030;
RA   Ji H., Ramsey M.R., Hayes D.N., Fan C., McNamara K., Kozlowski P.,
RA   Torrice C., Wu M.C., Shimamura T., Perera S.A., Liang M.C., Cai D.,
RA   Naumov G.N., Bao L., Contreras C.M., Li D., Chen L., Krishnamurthy J.,
RA   Koivunen J., Chirieac L.R., Padera R.F., Bronson R.T., Lindeman N.I.,
RA   Christiani D.C., Lin X., Shapiro G.I., Janne P.A., Johnson B.E.,
RA   Meyerson M., Kwiatkowski D.J., Castrillon D.H., Bardeesy N.,
RA   Sharpless N.E., Wong K.K.;
RT   "LKB1 modulates lung cancer differentiation and metastasis.";
RL   Nature 448:807-810(2007).
RN   [22]
RP   INVOLVEMENT IN LUNG CANCER.
RX   PubMed=17384680; DOI=10.1038/sj.onc.1210418;
RA   Matsumoto S., Iwakawa R., Takahashi K., Kohno T., Nakanishi Y.,
RA   Matsuno Y., Suzuki K., Nakamoto M., Shimizu E., Minna J.D., Yokota J.;
RT   "Prevalence and specificity of LKB1 genetic alterations in lung
RT   cancers.";
RL   Oncogene 26:5911-5918(2007).
RN   [23]
RP   INVOLVEMENT IN LUNG CANCER.
RX   PubMed=18594528; DOI=10.1038/sj.bjc.6604469;
RA   Koivunen J.P., Kim J., Lee J., Rogers A.M., Park J.O., Zhao X.,
RA   Naoki K., Okamoto I., Nakagawa K., Yeap B.Y., Meyerson M., Wong K.K.,
RA   Richards W.G., Sugarbaker D.J., Johnson B.E., Janne P.A.;
RT   "Mutations in the LKB1 tumour suppressor are frequently detected in
RT   tumours from Caucasian but not Asian lung cancer patients.";
RL   Br. J. Cancer 99:245-252(2008).
RN   [24]
RP   ALTERNATIVE SPLICING (ISOFORMS 1 AND 2), SUBCELLULAR LOCATION,
RP   PHOSPHORYLATION AT SER-428, AND MUTAGENESIS OF SER-428.
RX   PubMed=18854309; DOI=10.1074/jbc.M806153200;
RA   Denison F.C., Hiscock N.J., Carling D., Woods A.;
RT   "Characterization of an alternative splice variant of LKB1.";
RL   J. Biol. Chem. 284:67-76(2009).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-31, AND MASS
RP   SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-31, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [27]
RP   INVOLVEMENT IN LUNG CANCER.
RX   PubMed=20559149; DOI=10.1097/JTO.0b013e3181e05016;
RA   Gao B., Sun Y., Zhang J., Ren Y., Fang R., Han X., Shen L., Liu X.Y.,
RA   Pao W., Chen H., Ji H.;
RT   "Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung
RT   adenocarcinomas.";
RL   J. Thorac. Oncol. 5:1130-1135(2010).
RN   [28]
RP   FUNCTION.
RX   PubMed=21317932; DOI=10.1038/onc.2011.19;
RA   Hou X., Liu J.E., Liu W., Liu C.Y., Liu Z.Y., Sun Z.Y.;
RT   "A new role of NUAK1: directly phosphorylating p53 and regulating cell
RT   proliferation.";
RL   Oncogene 30:2933-2942(2011).
RN   [29]
RP   REVIEW ON FUNCTION.
RX   PubMed=21396365; DOI=10.1016/j.febslet.2011.03.010;
RA   Alexander A., Walker C.L.;
RT   "The role of LKB1 and AMPK in cellular responses to stress and
RT   damage.";
RL   FEBS Lett. 585:952-957(2011).
RN   [30]
RP   REVIEW ON INVOLVEMENT IN LUNG CANCER.
RX   PubMed=21380642; DOI=10.1007/s13238-011-1021-6;
RA   Gao Y., Ge G., Ji H.;
RT   "LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor
RT   suppressor.";
RL   Protein Cell 2:99-107(2011).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 43-347 IN COMPLEX WITH
RP   STRADA AND CAB39, ENZYME REGULATION, CHARACTERIZATION OF VARIANTS
RP   SPORADIC CANCER MET-66; GLY-86; ARG-123; SER-157; ASP-163; PRO-170;
RP   SER-171; ARG-174; TYR-176; ASN-177; GLU-181; GLN-199; THR-205;
RP   PHE-216; VAL-223; PRO-230; PRO-232; ARG-245; PRO-250; HIS-272;
RP   TYR-277; GLN-285 AND SER-315, AND MUTAGENESIS OF ARG-74; ASP-194 AND
RP   PHE-204.
RX   PubMed=19892943; DOI=10.1126/science.1178377;
RA   Zeqiraj E., Filippi B.M., Deak M., Alessi D.R., van Aalten D.M.;
RT   "Structure of the LKB1-STRAD-MO25 complex reveals an allosteric
RT   mechanism of kinase activation.";
RL   Science 326:1707-1711(2009).
RN   [32]
RP   VARIANT TGCT ASP-163.
RX   PubMed=9605748;
RA   Avizienyte E., Roth S., Loukola A., Hemminki A., Lothe R.A.,
RA   Stenwig A.E., Fossaa S.D., Salovaara R., Aaltonen L.A.;
RT   "Somatic mutations in LKB1 are rare in sporadic colorectal and
RT   testicular tumors.";
RL   Cancer Res. 58:2087-2090(1998).
RN   [33]
RP   VARIANTS COLORECTAL CANCER SER-171; LYS-199; ASN-208; ASP-215; LEU-354
RP   AND MET-367.
RX   PubMed=9731485;
RA   Dong S.M., Kim K.M., Kim S.Y., Shin M.S., Na E.Y., Lee S.H.,
RA   Park W.S., Yoo N.J., Jang J.J., Yoon C.Y., Kim J.W., Kim S.Y.,
RA   Yang Y.M., Kim S.H., Kim C.S., Lee J.Y.;
RT   "Frequent somatic mutations in serine/threonine kinase 11/Peutz-
RT   Jeghers syndrome gene in left-sided colon cancer.";
RL   Cancer Res. 58:3787-3790(1998).
RN   [34]
RP   VARIANT COLORECTAL CANCER HIS-314.
RX   PubMed=9809980;
RA   Resta N., Simone C., Mareni C., Montera M., Gentile M., Susca F.,
RA   Gristina R., Pozzi S., Bertario L., Bufo P., Carlomagno N.,
RA   Ingrosso M., Rossini F.P., Tenconi R., Guanti G.;
RT   "STK11 mutations in Peutz-Jeghers syndrome and sporadic colon
RT   cancer.";
RL   Cancer Res. 58:4799-4801(1998).
RN   [35]
RP   VARIANT PJS ASN-247 DEL.
RX   MEDLINE=98431000; PubMed=9760200; DOI=10.1007/s004390050801;
RA   Nakagawa H., Koyama K., Miyoshi Y., Ando H., Baba S., Watatani M.,
RA   Yasutomi M., Matsuura N., Monden M., Nakamura Y.;
RT   "Nine novel germline mutations of STK11 in ten families with Peutz-
RT   Jeghers syndrome.";
RL   Hum. Genet. 103:168-172(1998).
RN   [36]
RP   VARIANT GASTRIC CARCINOMA LEU-324.
RX   PubMed=9683800;
RA   Park W.S., Moon Y.W., Yang Y.M., Kim Y.S., Kim Y.D., Fuller B.G.,
RA   Vortmeyer A.O., Fogt F., Lubensky I.A., Zhuang Z.;
RT   "Mutations of the STK11 gene in sporadic gastric carcinoma.";
RL   Int. J. Oncol. 13:601-604(1998).
RN   [37]
RP   VARIANTS PJS PRO-67 AND 303-ILE--GLN-306 DELINS ASN.
RX   MEDLINE=98089041; PubMed=9428765; DOI=10.1038/34432;
RA   Hemminki A., Markie D., Tomlinson I., Avizienyte E., Roth S.,
RA   Loukola A., Bignell G., Warren W., Aminoff M., Hoeglund P.,
RA   Jaervinen H., Kristo P., Pelin K., Ridanpaeae M., Salovaara R.,
RA   Toro T., Bodmer W., Olschwang S., Olsen A.S., Stratton M.R.,
RA   de la Chapelle A., Aaltonen L.A.;
RT   "A serine/threonine kinase gene defective in Peutz-Jeghers syndrome.";
RL   Nature 391:184-187(1998).
RN   [38]
RP   VARIANT LUNG CANCER VAL-194.
RX   PubMed=10079245; DOI=10.1016/S0002-9440(10)65314-X;
RA   Avizienyte E., Loukola A., Roth S., Hemminki A., Tarkkanen M.,
RA   Salovaara R., Arola J., Butzow R., Husgafvel-Pursiainen K.,
RA   Kokkola A., Jarvinen H., Aaltonen L.A.;
RT   "LKB1 somatic mutations in sporadic cancers.";
RL   Am. J. Pathol. 154:677-681(1999).
RN   [39]
RP   VARIANTS PJS 162-ASN--MET-164; ASN-194 AND LYS-297.
RX   MEDLINE=99335262; PubMed=10408777;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:6<476::AID-HUMU7>3.3.CO;2-U;
RA   Westerman A.M., Entius M.M., Boor P.P.C., Koole R., de Baar E.,
RA   Offerhaus G.J.A., Lubinski J., Lindhout D., Halley D.J.J.,
RA   de Rooij F.W.M., Wilson J.H.P.;
RT   "Novel mutations in the LKB1/STK11 gene in Dutch Peutz-Jeghers
RT   families.";
RL   Hum. Mutat. 13:476-481(1999).
RN   [40]
RP   CHARACTERIZATION OF VARIANT TGCT ASP-163.
RX   PubMed=9887330; DOI=10.1093/hmg/8.1.45;
RA   Ylikorkala A., Avizienyte E., Tomlinson I.P., Tiainen M., Roth S.,
RA   Loukola A., Hemminki A., Johansson M., Sistonen P., Markie D.,
RA   Neale K., Phillips R., Zauber P., Twama T., Sampson J., Jaervinen H.,
RA   Maekelae T.P., Aaltonen L.A.;
RT   "Mutations and impaired function of LKB1 in familial and non-familial
RT   Peutz-Jeghers syndrome and a sporadic testicular cancer.";
RL   Hum. Mol. Genet. 8:45-51(1999).
RN   [41]
RP   VARIANT OVARIAN CARCINOMA LEU-281.
RX   PubMed=10429654;
RA   Nishioka Y., Kobayashi K., Sagae S., Sugimura M., Ishioka S.,
RA   Nagata M., Terasawa K., Tokino T., Kudo R.;
RT   "Mutational analysis of STK11 gene in ovarian carcinomas.";
RL   Jpn. J. Cancer Res. 90:629-632(1999).
RN   [42]
RP   VARIANTS MELANOMA ASP-49 AND ARG-135.
RX   PubMed=10201537; DOI=10.1046/j.1523-1747.1999.00551.x;
RA   Rowan A., Bataille V., MacKie R., Healy E., Bicknell D., Bodmer W.,
RA   Tomlinson I.;
RT   "Somatic mutations in the Peutz-Jeghers (LKB1/STKII) gene in sporadic
RT   malignant melanomas.";
RL   J. Invest. Dermatol. 112:509-511(1999).
RN   [43]
RP   VARIANT MELANOMA TYR-194.
RX   PubMed=10208439; DOI=10.1038/sj.onc.1202486;
RA   Guldberg P., thor Straten P., Ahrenkiel V., Seremet T., Kirkin A.F.,
RA   Zeuthen J.;
RT   "Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in
RT   malignant melanoma.";
RL   Oncogene 18:1777-1780(1999).
RN   [44]
RP   VARIANTS PJS CYS-239 AND SER-315.
RX   PubMed=12372054; DOI=10.1034/j.1399-0004.2002.620405.x;
RA   Scott R.J., Crooks R., Meldrum C.J., Thomas L., Smith C.J.A.,
RA   Mowat D., McPhillips M., Spigelman A.D.;
RT   "Mutation analysis of the STK11/LKB1 gene and clinical characteristics
RT   of an Australian series of Peutz-Jeghers syndrome patients.";
RL   Clin. Genet. 62:282-287(2002).
RN   [45]
RP   VARIANTS CERVICAL CANCER LYS-14; PRO-160 AND LEU-231, AND VARIANT
RP   CERVICAL CARCINOMA MET-66.
RX   PubMed=12533684;
RA   Kuragaki C., Enomoto T., Ueno Y., Sun H., Fujita M., Nakashima R.,
RA   Ueda Y., Wada H., Murata Y., Toki T., Konishi I., Fujii S.;
RT   "Mutations in the STK11 gene characterize minimal deviation
RT   adenocarcinoma of the uterine cervix.";
RL   Lab. Invest. 83:35-45(2003).
RN   [46]
RP   VARIANT [LARGE SCALE ANALYSIS] LYS-87.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [47]
RP   VARIANT PJS GLY-16.
RX   PubMed=21411391; DOI=10.1016/j.clinre.2010.11.008;
RA   Liu L., Du X., Nie J.;
RT   "A novel de novo mutation in LKB1 gene in a Chinese Peutz Jeghers
RT   syndrome patient significantly diminished p53 activity.";
RL   Clin. Res. Hepatol. Gastroenterol. 35:221-226(2011).
CC   -!- FUNCTION: Tumor suppressor serine/threonine-protein kinase that
CC       controls the activity of AMP-activated protein kinase (AMPK)
CC       family members, thereby playing a role in various processes such
CC       as cell metabolism, cell polarity, apoptosis and DNA damage
CC       response. Acts by phosphorylating the T-loop of AMPK family
CC       proteins, leading to promote their activity: phosphorylates
CC       PRKAA1, PRKAA2, BRSK1, BRSK2, MARK1, MARK2, MARK3, MARK4, NUAK1,
CC       NUAK2, SIK1, SIK2, SIK3 and SNRK but not MELK. Also phosphorylates
CC       non-AMPK family proteins such as STRADA and possibly p53/TP53.
CC       Acts as a key upstream regulator of AMPK by mediating
CC       phosphorylation and activation of AMPK catalytic subunits PRKAA1
CC       and PRKAA2: it thereby regulates inhibition of signaling pathways
CC       that promote cell growth and proliferation when energy levels are
CC       low, glucose homeostasis in liver, activation of autophagy when
CC       cells undergo nutrient deprivation, B-cell differentiation in the
CC       germinal center in response to DNA damage. Also acts as a
CC       regulator of cellular polarity by remodeling the actin
CC       cytoskeleton. Required for cortical neurons polarization by
CC       mediating phosphorylation and activation of BRSK1 and BRSK2,
CC       leading to axon initiation and specification. Involved in DNA
CC       damage response: interacts with p53/TP53 and recruited to the
CC       CDKN1A/WAF1 promoter to participate in transcription activation.
CC       Able to phosphorylate p53/TP53; the relevance of such result in
CC       vivo is however unclear and phosphorylation may be indirect and
CC       mediated by downstream STK11/LKB1 kinase NUAK1 Also acts as a
CC       mediator p53/TP53-dependent apoptosis via interaction with
CC       p53/TP53: translocates to mitochondrion during apoptosis and
CC       regulates p53/TP53-dependent apoptosis pathways.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR: Magnesium or Manganese.
CC   -!- ENZYME REGULATION: Activated by forming a complex with STRAD
CC       (STRADA or STRADB) and CAB39/MO25 (CAB39/MO25alpha or
CC       CAB39L/MO25beta): STRADA (or STRADB)-binding promotes a
CC       conformational change of STK11/LKB1 in an active conformation,
CC       which is stabilized by CAB39/MO25alpha (or CAB39L/MO25beta)
CC       interacting with the STK11/LKB1 activation loop.
CC   -!- SUBUNIT: Catalytic component of a trimeric complex composed of
CC       STK11/LKB1, STRAD (STRADA or STRADB) and CAB39/MO25
CC       (CAB39/MO25alpha or CAB39L/MO25beta): the complex tethers
CC       STK11/LKB1 in the cytoplasm and stimulates its catalytic activity.
CC       Found in a ternary complex composed of SMAD4, STK11/LKB1 and
CC       STK11IP. Interacts with p53/TP53, SMAD4, STK11IP and WDR6.
CC   -!- INTERACTION:
CC       Q9Y376:CAB39; NbExp=4; IntAct=EBI-306838, EBI-306905;
CC       Q96L34:MARK4; NbExp=2; IntAct=EBI-306838, EBI-302319;
CC       Q7RTN6:STRADA; NbExp=9; IntAct=EBI-306838, EBI-1109114;
CC       Q9C0K7:STRADB; NbExp=6; IntAct=EBI-306838, EBI-306893;
CC       Q8NFZ5:TNIP2; NbExp=4; IntAct=EBI-306838, EBI-359372;
CC       Q9NNW5:WDR6; NbExp=3; IntAct=EBI-306838, EBI-1568315;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Membrane (By
CC       similarity). Mitochondrion. Note=A small fraction localizes at
CC       membranes (By similarity). Relocates to the cytoplasm when bound
CC       to STRAD (STRADA or STRADB) and CAB39/MO25 (CAB39/MO25alpha or
CC       CAB39L/MO25beta). Translocates to mitochondrion during apoptosis.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=LKB1(L);
CC         IsoId=Q15831-1; Sequence=Displayed;
CC       Name=2; Synonyms=LKB1(S);
CC         IsoId=Q15831-2; Sequence=VSP_041746;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed. Strongest expression
CC       in testis and fetal liver.
CC   -!- PTM: Phosphorylated by ATM at Thr-363 following ionizing
CC       radiations (IR). Phosphorylation at Ser-428 by RPS6KA1 and/or some
CC       PKA is required to inhibit cell growth. Phosphorylation at Ser-428
CC       is also required during neuronal polarization to mediate
CC       phosphorylation of BRSK1 and BRSK2 (By similarity).
CC   -!- DISEASE: Defects in STK11 are a cause of Peutz-Jeghers syndrome
CC       (PJS) [MIM:175200]. PJS is a rare hereditary disease in which
CC       there is predisposition to benign and malignant tumors of many
CC       organ systems. PJS is an autosomal dominant disorder characterized
CC       by melanocytic macules of the lips, multiple gastrointestinal
CC       hamartomatous polyps and an increased risk for various neoplasms,
CC       including gastrointestinal cancer.
CC   -!- DISEASE: Defects in STK11 have been associated with testicular
CC       germ cell tumor (TGCT) [MIM:273300]. A common solid malignancy in
CC       males. Germ cell tumors of the testis constitute 95% of all
CC       testicular neoplasms.
CC   -!- DISEASE: Note=Defects in STK11 are associated with some sporadic
CC       cancers, especially lung cancers. Frequently mutated and
CC       inactivated in non-small cell lung cancer (NSCLC). Defects promote
CC       lung cancerigenesis process, especially lung cancer progression
CC       and metastasis. Confers lung adenocarcinoma the ability to trans-
CC       differentiate into squamous cell carcinoma. Also able to promotes
CC       lung cancer metastasis, via both cancer-cell autonomous and non-
CC       cancer-cell autonomous mechanisms.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK
CC       Ser/Thr protein kinase family. LKB1 subfamily.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/STK11ID292.html";
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/STK11";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=PJS entry;
CC       URL="http://en.wikipedia.org/wiki/PJS";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U63333; AAB05809.1; -; mRNA.
DR   EMBL; AF035625; AAC39527.1; -; mRNA.
DR   EMBL; AF032984; AAB97833.1; -; Genomic_DNA.
DR   EMBL; AF055327; AAC15742.1; -; Genomic_DNA.
DR   EMBL; AF055320; AAC15742.1; JOINED; Genomic_DNA.
DR   EMBL; AF055321; AAC15742.1; JOINED; Genomic_DNA.
DR   EMBL; AF055322; AAC15742.1; JOINED; Genomic_DNA.
DR   EMBL; AF055323; AAC15742.1; JOINED; Genomic_DNA.
DR   EMBL; AF055324; AAC15742.1; JOINED; Genomic_DNA.
DR   EMBL; AF055325; AAC15742.1; JOINED; Genomic_DNA.
DR   EMBL; AF055326; AAC15742.1; JOINED; Genomic_DNA.
DR   EMBL; AK314858; BAG37374.1; -; mRNA.
DR   EMBL; AC011544; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC004221; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471139; EAW69540.1; -; Genomic_DNA.
DR   EMBL; BC007981; AAH07981.1; -; mRNA.
DR   EMBL; BC019334; AAH19334.1; -; mRNA.
DR   IPI; IPI01024704; -.
DR   IPI; IPI01024909; -.
DR   RefSeq; NP_000446.1; NM_000455.4.
DR   UniGene; Hs.515005; -.
DR   PDB; 2WTK; X-ray; 2.65 A; C/F=43-347.
DR   PDBsum; 2WTK; -.
DR   ProteinModelPortal; Q15831; -.
DR   SMR; Q15831; 45-342.
DR   DIP; DIP-31317N; -.
DR   IntAct; Q15831; 30.
DR   MINT; MINT-204048; -.
DR   STRING; Q15831; -.
DR   PhosphoSite; Q15831; -.
DR   DMDM; 3024670; -.
DR   PRIDE; Q15831; -.
DR   DNASU; 6794; -.
DR   Ensembl; ENST00000326873; ENSP00000324856; ENSG00000118046.
DR   Ensembl; ENST00000405031; ENSP00000384275; ENSG00000118046.
DR   GeneID; 6794; -.
DR   KEGG; hsa:6794; -.
DR   UCSC; uc002lrl.1; human.
DR   CTD; 6794; -.
DR   GeneCards; GC19P001205; -.
DR   H-InvDB; HIX0014573; -.
DR   HGNC; HGNC:11389; STK11.
DR   HPA; CAB016231; -.
DR   HPA; CAB022105; -.
DR   HPA; HPA017254; -.
DR   MIM; 175200; phenotype.
DR   MIM; 273300; phenotype.
DR   MIM; 602216; gene.
DR   neXtProt; NX_Q15831; -.
DR   Orphanet; 2869; Peutz-Jeghers syndrome.
DR   PharmGKB; PA36198; -.
DR   eggNOG; COG0515; -.
DR   GeneTree; ENSGT00530000063214; -.
DR   HOGENOM; HBG446083; -.
DR   HOVERGEN; HBG054467; -.
DR   InParanoid; Q15831; -.
DR   KO; K07298; -.
DR   OMA; PFAADDT; -.
DR   OrthoDB; EOG49CQ7R; -.
DR   PhylomeDB; Q15831; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   Reactome; REACT_111102; Signal Transduction.
DR   Reactome; REACT_111217; Metabolism.
DR   Reactome; REACT_11163; Activated AMPK stimulates fatty-acid oxidation in muscle.
DR   NextBio; 26541; -.
DR   ArrayExpress; Q15831; -.
DR   Bgee; E7EW76; -.
DR   CleanEx; HS_STK11; -.
DR   Genevestigator; Q15831; -.
DR   GermOnline; ENSG00000118046; Homo sapiens.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; ISS:UniProtKB.
DR   GO; GO:0016020; C:membrane; ISS:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0002039; F:p53 binding; IDA:UniProtKB.
DR   GO; GO:0030295; F:protein kinase activator activity; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0043276; P:anoikis; IMP:BHF-UCL.
DR   GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0007050; P:cell cycle arrest; IDA:UniProtKB.
DR   GO; GO:0006112; P:energy reserve metabolic process; TAS:Reactome.
DR   GO; GO:0030010; P:establishment of cell polarity; ISS:UniProtKB.
DR   GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0030308; P:negative regulation of cell growth; ISS:UniProtKB.
DR   GO; GO:0030511; P:positive regulation of transforming growth factor beta receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0042304; P:regulation of fatty acid biosynthetic process; TAS:Reactome.
DR   GO; GO:0046320; P:regulation of fatty acid oxidation; TAS:Reactome.
DR   GO; GO:0006974; P:response to DNA damage stimulus; IEA:UniProtKB-KW.
DR   GO; GO:0010212; P:response to ionizing radiation; ISS:UniProtKB.
DR   GO; GO:0072332; P:signal transduction by p53 class mediator resulting in induction of apoptosis; IDA:UniProtKB.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   GO; GO:0001944; P:vasculature development; ISS:UniProtKB.
DR   InterPro; IPR020636; Ca/CaM-dep_Ca-dep_prot_Kinase.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR002290; Ser/Thr_dual-sp_kinase_dom.
DR   InterPro; IPR015735; Ser/Thr_kinase-11.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR24347; PTHR24347; 1.
DR   PANTHER; PTHR24347:SF41; PTHR24347:SF41; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; ATP-binding; Autophagy;
KW   Cell cycle; Complete proteome; Cytoplasm; Disease mutation;
KW   DNA damage; Kinase; Lipoprotein; Magnesium; Manganese; Membrane;
KW   Metal-binding; Mitochondrion; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Prenylation; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Tumor suppressor.
FT   CHAIN         1    433       Serine/threonine-protein kinase STK11.
FT                                /FTId=PRO_0000086699.
FT   DOMAIN       49    309       Protein kinase.
FT   NP_BIND      55     63       ATP (By similarity).
FT   ACT_SITE    176    176       Proton acceptor.
FT   BINDING      78     78       ATP (Probable).
FT   MOD_RES      31     31       Phosphoserine.
FT   MOD_RES     189    189       Phosphothreonine; by autocatalysis.
FT   MOD_RES     325    325       Phosphoserine (By similarity).
FT   MOD_RES     336    336       Phosphothreonine; by autocatalysis.
FT   MOD_RES     363    363       Phosphothreonine; by ATM and
FT                                autocatalysis.
FT   MOD_RES     428    428       Phosphoserine; by PKA and RPS6KA1.
FT   LIPID       430    430       S-farnesyl cysteine (By similarity).
FT   VAR_SEQ     371    433       QVPEEEASHNGQRRGLPKAVCMNGTEAAQLSTKSRAEGRAP
FT                                NPARKACSASSKIRRLSACKQQ -> GEEASEAGLRAERGL
FT                                QKSEGSDLSGEEASRPAPQ (in isoform 2).
FT                                /FTId=VSP_041746.
FT   VARIANT      14     14       E -> K (in cervical cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_065627.
FT   VARIANT      16     16       E -> G (in PJS).
FT                                /FTId=VAR_065628.
FT   VARIANT      49     49       Y -> D (in melanoma; sporadic malignant;
FT                                somatic mutation).
FT                                /FTId=VAR_033138.
FT   VARIANT      66     66       V -> M (in cervical carcinoma; somatic
FT                                mutation).
FT                                /FTId=VAR_065629.
FT   VARIANT      67     67       L -> P (in PJS).
FT                                /FTId=VAR_006202.
FT   VARIANT      86     86       R -> G (in sporadic cancer; somatic
FT                                mutation; no effect on kinase activity
FT                                nor in heterotrimeric complex assembly
FT                                with STRADA and CAB39).
FT                                /FTId=VAR_065630.
FT   VARIANT      87     87       R -> K (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_041139.
FT   VARIANT     123    123       Q -> R (in sporadic cancer; somatic
FT                                mutation; no effect on kinase activity
FT                                nor in heterotrimeric complex assembly
FT                                with STRADA and CAB39).
FT                                /FTId=VAR_065631.
FT   VARIANT     135    135       G -> R (in melanoma; sporadic malignant;
FT                                somatic mutation).
FT                                /FTId=VAR_033139.
FT   VARIANT     157    157       F -> S (in sporadic cancer; somatic
FT                                mutation; impairs heterotrimeric complex
FT                                assembly with STRADA and CAB39).
FT                                /FTId=VAR_065632.
FT   VARIANT     160    160       L -> P (in cervical cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_065633.
FT   VARIANT     162    164       DGL -> NDM (in PJS).
FT                                /FTId=VAR_007920.
FT   VARIANT     163    163       G -> D (in TGCT; a tumor with seminoma
FT                                and teratoma components; associated with
FT                                severely impaired but detectable kinase
FT                                activity; somatic mutation; impairs
FT                                heterotrimeric complex assembly with
FT                                STRADA and CAB39).
FT                                /FTId=VAR_033140.
FT   VARIANT     170    170       Q -> P (in sporadic cancer; somatic
FT                                mutation; impairs heterotrimeric complex
FT                                assembly with STRADA and CAB39).
FT                                /FTId=VAR_065634.
FT   VARIANT     171    171       G -> S (in colorectal cancer; somatic
FT                                mutation; impairs heterotrimeric complex
FT                                assembly with STRADA and CAB39).
FT                                /FTId=VAR_065635.
FT   VARIANT     174    174       H -> R (in sporadic cancer; somatic
FT                                mutation; impairs heterotrimeric complex
FT                                assembly with STRADA and CAB39).
FT                                /FTId=VAR_065636.
FT   VARIANT     176    176       D -> Y (in sporadic cancer; somatic
FT                                mutation; Loss of kinase activity).
FT                                /FTId=VAR_065637.
FT   VARIANT     177    177       I -> N (in sporadic cancer; somatic
FT                                mutation; impairs heterotrimeric complex
FT                                assembly with STRADA and CAB39).
FT                                /FTId=VAR_065638.
FT   VARIANT     181    181       N -> E (in sporadic cancer; somatic
FT                                mutation; impairs heterotrimeric complex
FT                                assembly with STRADA and CAB39; requires
FT                                2 nucleotide substitutions).
FT                                /FTId=VAR_065639.
FT   VARIANT     194    194       D -> N (in PJS).
FT                                /FTId=VAR_007921.
FT   VARIANT     194    194       D -> V (in lung cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_065640.
FT   VARIANT     194    194       D -> Y (in melanoma; sporadic malignant;
FT                                somatic mutation).
FT                                /FTId=VAR_033141.
FT   VARIANT     199    199       E -> K (in colorectal cancer; somatic
FT                                mutation; impaired kinase activity).
FT                                /FTId=VAR_065641.
FT   VARIANT     199    199       E -> Q (in sporadic cancer; somatic
FT                                mutation; does not affect kinase
FT                                activity).
FT                                /FTId=VAR_065642.
FT   VARIANT     205    205       A -> T (in sporadic cancer; somatic
FT                                mutation; no effect heterotrimeric
FT                                complex assembly with STRADA and CAB39).
FT                                /FTId=VAR_065643.
FT   VARIANT     208    208       D -> N (in colorectal cancer; somatic
FT                                mutation; no effect heterotrimeric
FT                                complex assembly with STRADA and CAB39).
FT                                /FTId=VAR_065644.
FT   VARIANT     215    215       G -> D (in colorectal cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_065645.
FT   VARIANT     216    216       S -> F (in sporadic cancer; somatic
FT                                mutation; impairs heterotrimeric complex
FT                                assembly with STRADA and CAB39).
FT                                /FTId=VAR_065646.
FT   VARIANT     223    223       E -> V (in sporadic cancer; somatic
FT                                mutation; impairs heterotrimeric complex
FT                                assembly with STRADA and CAB39).
FT                                /FTId=VAR_065647.
FT   VARIANT     230    230       T -> P (in sporadic cancer; somatic
FT                                mutation; no effect heterotrimeric
FT                                complex assembly with STRADA and CAB39).
FT                                /FTId=VAR_065648.
FT   VARIANT     231    231       F -> L (in cervical cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_065649.
FT   VARIANT     232    232       S -> P (in sporadic cancer; somatic
FT                                mutation; no effect heterotrimeric
FT                                complex assembly with STRADA and CAB39).
FT                                /FTId=VAR_065650.
FT   VARIANT     239    239       W -> C (in PJS; late onset suggests
FT                                reduced penetrance).
FT                                /FTId=VAR_033142.
FT   VARIANT     245    245       L -> R (in sporadic cancer; somatic
FT                                mutation; impairs heterotrimeric complex
FT                                assembly with STRADA and CAB39).
FT                                /FTId=VAR_065651.
FT   VARIANT     247    247       Missing (in PJS).
FT                                /FTId=VAR_006203.
FT   VARIANT     250    250       T -> P (in sporadic cancer; somatic
FT                                mutation; impairs heterotrimeric complex
FT                                assembly with STRADA and CAB39).
FT                                /FTId=VAR_065652.
FT   VARIANT     272    272       Y -> H (in sporadic cancer; somatic
FT                                mutation; no effect on kinase activity
FT                                nor in heterotrimeric complex assembly
FT                                with STRADA and CAB39).
FT                                /FTId=VAR_065653.
FT   VARIANT     277    277       D -> Y (in sporadic cancer; somatic
FT                                mutation; no effect on kinase activity
FT                                nor in heterotrimeric complex assembly
FT                                with STRADA and CAB39).
FT                                /FTId=VAR_065654.
FT   VARIANT     281    281       P -> L (in ovarian carcinoma; somatic
FT                                mutation).
FT                                /FTId=VAR_065655.
FT   VARIANT     285    285       L -> Q (in sporadic cancer; somatic
FT                                mutation; impairs heterotrimeric complex
FT                                assembly with STRADA and CAB39).
FT                                /FTId=VAR_065656.
FT   VARIANT     297    297       R -> K (in PJS).
FT                                /FTId=VAR_007922.
FT   VARIANT     303    306       IRQH -> N (in PJS).
FT                                /FTId=VAR_033143.
FT   VARIANT     314    314       P -> H (in colorectal cancer; no effect
FT                                heterotrimeric complex assembly with
FT                                STRADA and CAB39).
FT                                /FTId=VAR_065657.
FT   VARIANT     315    315       P -> S (in PJS; pathogenicity uncertain;
FT                                no effect heterotrimeric complex assembly
FT                                with STRADA and CAB39).
FT                                /FTId=VAR_033144.
FT   VARIANT     324    324       P -> L (in gastric carcinoma; no effect
FT                                heterotrimeric complex assembly with
FT                                STRADA and CAB39).
FT                                /FTId=VAR_065658.
FT   VARIANT     354    354       F -> L (in colorectal cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_065659.
FT   VARIANT     367    367       T -> M (in colorectal cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_065660.
FT   MUTAGEN      74     74       R->A: Impaired formation of a
FT                                heterotrimeric complex with STRADA and
FT                                CAB39; when associated with A-204.
FT   MUTAGEN      78     78       K->M: Loss of kinase activity, leading to
FT                                reduced autophosphorylation and acting as
FT                                a dominant-negative mutant.
FT   MUTAGEN     189    189       T->A: Reduced phosphorylation.
FT   MUTAGEN     194    194       D->A: Loss of kinase activity.
FT   MUTAGEN     204    204       F->A: No effect. Impaired formation of a
FT                                heterotrimeric complex with STRADA and
FT                                CAB39; when associated with A-74.
FT   MUTAGEN     428    428       S->A,E: No effect on kinase activity.
FT   STRAND       63     68
FT   TURN         69     71
FT   STRAND       74     80
FT   HELIX        82     87
FT   HELIX        93    102
FT   STRAND      113    118
FT   STRAND      125    130
FT   HELIX       137    142
FT   HELIX       150    153
FT   HELIX       157    161
FT   HELIX       165    169
FT   STRAND      182    184
FT   STRAND      190    192
FT   HELIX       217    219
FT   HELIX       222    225
FT   HELIX       235    240
FT   HELIX       244    249
FT   HELIX       260    266
FT   HELIX       281    286
FT   TURN        294    296
FT   HELIX       300    305
FT   HELIX       307    310
FT   HELIX       339    341
SQ   SEQUENCE   433 AA;  48636 MW;  6DF4C37AB7A89569 CRC64;
     MEVVDPQQLG MFTEGELMSV GMDTFIHRID STEVIYQPRR KRAKLIGKYL MGDLLGEGSY
     GKVKEVLDSE TLCRRAVKIL KKKKLRRIPN GEANVKKEIQ LLRRLRHKNV IQLVDVLYNE
     EKQKMYMVME YCVCGMQEML DSVPEKRFPV CQAHGYFCQL IDGLEYLHSQ GIVHKDIKPG
     NLLLTTGGTL KISDLGVAEA LHPFAADDTC RTSQGSPAFQ PPEIANGLDT FSGFKVDIWS
     AGVTLYNITT GLYPFEGDNI YKLFENIGKG SYAIPGDCGP PLSDLLKGML EYEPAKRFSI
     RQIRQHSWFR KKHPPAEAPV PIPPSPDTKD RWRSMTVVPY LEDLHGADED EDLFDIEDDI
     IYTQDFTVPG QVPEEEASHN GQRRGLPKAV CMNGTEAAQL STKSRAEGRA PNPARKACSA
     SSKIRRLSAC KQQ
//
